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ABSTRACT
Introduction: Several therapeutic options are
available for the treatment of vitiligo; among
these phototherapy and topical steroids are the
most widely documented. A topical formulation
of 0.05% clobetasol propionate foam (CPF) has
been introduced in the market, but no data are
available about the efficacy and tolerability of
this new formulation in the treatment of
vitiligo. The aim of this study was to
investigate the efficacy and tolerability of CPF
in the treatment of vitiligo, in comparison
with narrowband-ultraviolet B (NB-UVB)
phototherapy.
Methods: The medical records of the first 60
vitiligo patients treated with NB-UVB
phototherapy or with CPF were selected.
Response to the treatment was determined for
each anatomic site (neck, upper and lower
limbs, trunk, hands/wrists, feet/ankles). Based
on the area of repigmentation, treatment
outcome was calculated according to a scale
ranging from 0 (absent) to 4 (excellent). The
incidence of adverse effects was also noted as a
secondary endpoint. Significance level was set
at P = 0.05.
Results: For each anatomic site, statistical
analyses demonstrated that the efficacy of CPF
was significantly higher compared to NB-UVB.
Side effects occurred in 4 patients (13.33%) in
the CPF group compared to none in the NB-
UVB group.
Discussion: Clobetasol propionate has been
used in vitiligo in different vehicles, but never
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in foam. The data showed that CPF is effective
and seems to be superior to NB-UVB
phototherapy, with furthermore a good safety
profile.
Conclusion: This new foam formulation of
clobetasol propionate may expand the options
currently available for vitiligo therapy;
however, further investigations are needed to
confirm our preliminary observations.
Keywords: Clobetasol propionate foam;
Narrowband-ultraviolet B phototherapy;
VersaFoam; Vitiligo
INTRODUCTION
The treatment of vitiligo is not well codified and
often results are stressful and unsatisfying. A
wide range of therapeutic options have been
proposed including topical corticosteroids,
ultraviolet radiations, either psoralens with
ultraviolet A (PUVA) or narrowband-ultraviolet
B (NB-UVB), lasers, surgical treatments, and
more recently topical calcineurin inhibitors
[1–3]. However, no treatment provides truly
satisfactory results.
NB-UVB phototherapy is considered a first-
line treatment for extensive vitiligo because of
the relatively good efficacy and the excellent
tolerance [4]. On the other hand, the topical
steroids are indicated for the therapy of limited
areas of vitiligo [5]. Clobetasol propionate is the
most powerful of these drugs and it is available
in the form of lotion, ointment, cream,
emollient cream, solution, shampoo, and
foam. A topical formulation of 0.05%
clobetasol propionate foam (CPF; VersaFoam,
Connetics, Palo Alto, CA, USA) has been
available since 2006. Compared to cream and
ointment this formulation leaves only a very
little residue deposited on the skin with a better
acceptability profile and with a greater positive
effect on quality of life [6]. The cutaneous and
systemic adverse effects of topical steroids
depend on several factors including the
activity, the systemic absorption and the
bioavailability of the drug, the dose and the
duration of the treatment. Clobetasol
propionate cream or ointment has already
been reported in the therapy of vitiligo [7–9],
but no data are available regarding the use of
foam formulation.
The aim of this study was to investigate the
efficacy and tolerability of CPF in the treatment
of vitiligo, in comparison with NB-UVB
phototherapy.
METHODS
Study Design
The study subjects were selected from a group of
adult patients with vitiligo vulgaris who were
referred consecutively to the Departments of
Dermatology of the Universities of Udine and
Trieste in Italy from October 2009 to April 2010.
For the purpose of this study, only patients who
had completed the treatment protocol with CPF or
NB-UVB were considered. To be included, the
patients had to have performed a clinical
evaluation before the start, at the half and at the
end of therapy. Patients who had discontinued the
treatment due to side effects were still recruited.
Demographic data (age, sex, Fitzpatrick’s skin
phototype, comorbidities) and characteristics of
vitiligo (pattern, location,duration, familyhistory)
had to be obtained from each patient. For each
visit, data of physical examination and of possible
adverse effects had to be obtained and digital
photographs of the lesions taken both with normal
ambient light and with Wood’s lamp in standard
pose. Patients who had received other treatments
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for vitiligo in the month prior to the start of CPF or
NB-UVB were excluded from the study as well as
those with infections, neurological or psychiatric
disorders, immune defects, heart disease, renal
failure, malignancy, history of photosensitivity or
photomediated disorders, and a positive
antinuclear antibody titer. Women who were
pregnant and breastfeeding and patients taking
known photosensitizer drugs or
immunosuppressive therapy were also excluded
from the study. The first 30 adult patients treated
with UVB phototherapy and the first 30 treated
with CPF who fulfilled these criteria were included
in the study. All patients had nonsegmental
vitiligo for almost 1 year (chronic) without any
new depigmented patches in the past 12 months
(stable).
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. All the patients had given
informed written consent to the treatment
and to the photos.
According to the treatment received,
patients were categorized into two groups (A
and B); patients in group A had undergone NB-
UVB phototherapy while group B patients had
received CPF [VersaFoam-hydroethanolic foam
(HF) formulation containing 60% ethanol].
Twenty-two patients (36.6%), 6 in group A
and 16 in group B, had never been treated for
vitiligo, while the remaining 38 patients had
previously received treatment with other topical
steroids, calcineurin inhibitors, PUVA, and
topical calcipotriol with unsatisfactory results.
Therapeutic Regimen
Group A patients had been treated with NB-
UVB as monotherapy using the N-LINE pro
cabin (Saalmann medical GmbH,
Hiddenhausen, Germany) with a digital timer.
Phototherapy had been given thrice a week on
non-consecutive days, for a maximum of
6 months or 50 sessions in total. Initial
phototesting had not been done. The minimal
erythematous dose (MED) was pre-determined
(280 mJ/cm2) according to the concept that the
depigmented skin lesions of vitiligo are
considered as phototype I [10]. The initial dose
in all patients was 280 mJ/cm2, with subsequent
15% increments from the previous dosage in
every session until minimal erythema appeared.
Thereafter, the dose had been maintained until
the sixth month therapy completion or till a
complete repigmentation was achieved,
whichever occurred first. In case of
symptomatic erythema (burning, pain) or
blistering, the irradiation dose had been
decreased by 15%. Standard photo-protection
protocol for NB-UVB had been observed. During
treatment, the genital area had been shielded
and the eyes are protected by UV-blocking
goggles. Barring these protected areas, whole-
body irradiation was performed. In case of
vitiligo present in the eyelid area, patients
were asked not to wear goggles but had been
advised to keep their eyes shut during the
sessions. Patients were advised to apply a very
high protection sunscreen with frequent
reapplication and incorporation of sun
avoidance techniques (avoidance of midday
sun and wearing a hat).
Group B patients had been instructed to
apply CPF, with a fine massage until the product
was fully absorbed, the smallest amount of foam
necessary to cover all the lesions twice a day for
5 days/week for 12 weeks. Subjects dispensed
foam into the cap of the container and applied a
small amount of foam to the vitiligo lesions.
One cap of foam weighs 3.5 g, the maximum
amount the subject could use for each
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application. When one cup of foam was not
sufficient to cover all the lesions, for safety
reasons, the patients were suggested to treat
only the anatomical site they considered the
most disturbing from an esthetic and
psychological point of view. Face and
intertriginous areas were excluded from the
treatment and patients were also asked to stop
the treatment in case of occurrence of side
effects such as infection signs, atrophy,
teleangectasy, and folliculitis. All patients were
also asked to avoid the direct UV exposition
during the whole period of study and were
advised to apply a very high protection
sunscreen with frequent reapplication and
incorporation of sun avoidance techniques
(avoidance of midday sun and wearing a hat).
Clinical Evaluation
The digital lesional photographs, both with
normal ambient light and with Wood’s lamp
obtained in a standard pose before the start, at
the half and at the end of therapy were
examined visually by two different
dermatologists and evaluated through single-
case discussion between these two experts.
Response to the treatment was determined for
each anatomic site (neck, upper and lower
limbs, trunk, hands/wrists, feet/ankles) by
assigning the entire lesion a 0% score before
treatment to indicate a baseline of no
repigmentation and a second percentage value
at the end of the study to represent the level of
repigmentation. The area of repigmentation
was analyzed by serial mapping of body
lesions. Treatment outcome was calculated for
each anatomic site according to a scale ranging
from 0 to 4 and classified as ‘0, absent’ (0%), ‘1,
poor’ (1–25%), ‘2, moderate’ (26–50%), ‘3, good’
(51–75%), and ‘4, excellent’ ([75%) performing
a visual comparison with a pre-treatment
photography under the same lighting
conditions.
Data about potential repigmentation due to
NB-UVB of face and intertriginous areas were
not reported because in the CPF group those
anatomic sites have not been treated since the
risk of severe side effects linked to the twice-
daily application of a superpotent steroid.
During the whole period of the study, any
possible side effects were recorded.
Statistical Analysis
Characteristics of the study population are
described using mean and standard deviation
or median and range for continuous or ordinal
variables and as frequencies and percentages for
categorical variables. Normality was assessed
with the Shapiro–Wilk test. Analyses for the
efficacy of each treatment were based on the
comparison between the before treatment
assessment and the last clinical evaluation.
Comparisons between treatment groups were
performed using T test or Mann–Whitney rank
test for continuous or ordinal variables based on
the results of the Shapiro–Wilk test, and Chi-
square or Fisher’s exact test for categorical
variables, as appropriate. Significance level was
set at P = 0.05. All analyses were performed
using Stata (version SE 12.1, Statacorp LP,
College Station, TX, USA).
RESULTS
Patient Characteristics
Baseline characteristics of the study population
are summarized in Table 1. The mean age of the
patients treated with CPF was slightly lower
compared with those who had received NB-
UVB. There was no significant difference in the
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distribution of sex, pattern, Fitzpatrick’s skin
phototypes, and family history of vitiligo
between the NB-UVB treated group and the
CPF-treated group. The duration of vitiligo was
significantly shorter in the NB-UVB group
compared with the CPF group. Among the
comorbidities, thyroid diseases were more
frequent in the CPF-treated group.
Comparison Between NB-UVB and CPF
Treatments
The results of NB-UVB and CPF treatments in
patients with vitiligo are summarized in Table 2.
The number of patients treated for each
anatomic site was homogeneous between the
two groups.
Overall, for each site, the efficacy of CPF was
significantly higher compared with NB-UVB
(Fig. 1). In the CPF-treated group, a variable
repigmentation was found, from poor to
excellent, at neck, upper and lower limbs,
trunk, and hand/wrists (Fig. 2). Lack of
repigmentation was observed at feet/ankles in
6 of 11 treated patients. In the NB-UVB group at
feet/ankles, no sign of repigmentation was
found in any of the 12 treated patients. In
addition, lack of repigmentation was observed
at hands/wrists in 13 of 16 treated patients. In
the remaining anatomical sites, variable levels
of repigmentation were recorded. In the NB-
UVB group, none of the patients reported
adverse effects throughout the study period. In
the CPF group, a woman stopped treatment due
to the appearance of diffuse edema. Three other
patients reported a slight and transient
erythema with itching which disappeared after
the next application without having to
discontinue the treatment. The difference in
occurrence of side effects observed in the two
groups was not significant (Fisher’s test
P = 0.112).
DISCUSSION
Several therapeutic options have been proposed
for vitiligo, but successful repigmentation
occurs only in about half of the treated
patients. Topical and systemic corticosteroids,
topical calcineurin inhibitors, calcipotriol,
phototherapy, excimer laser and surgical
methods, such as skin/single-hair grafting, or
autologous cultured melanocyte or epidermal
suspension transplantations have been used
with different results [2, 3]. Among these
treatments, phototherapy and topical steroids
are the most widely documented [5, 10].
Several studies have been published on the
NB-UVB treatment of vitiligo in different
populations of patients with variable, but
usually good, responses [11–16]. Overall NB-
UVB was accepted and well tolerated by most
patients. The most common short-time side
effects include erythema, pruritus, and xerosis;
moreover, NB-UVB has been known to cause
phototoxic reactions and tanning. There are
little long-term data on the use of UVB in the
treatment of vitiligo, but one potential adverse
effect could be an increased chance of
nonmelanoma skin cancer in vitiliginous skin
receiving NB-UVB [4]. The clinical efficacy of
clobetasol propionate has been known for many
years for the treatment of vitiligo [17, 18]. A
topical formulation of this superpotent
corticosteroid in thermophobic foam has been
reported as an effective treatment in psoriasis
[19], chronic hand dermatitis [20], atopic
dermatitis [21], alopecia areata [22], and
delayed pressure urticaria [23]. Clobetasol
propionate has been used in vitiligo in
different vehicles, but never in foam. The
results of this study demonstrate that in a
population of patients with vitiligo CPF can be
an effective option and its clinical efficacy
seems to be superior to NB-UVB phototherapy.
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Till now, to the best of the authors’ knowledge,
no study of comparison between UVB and
clobetasol propionate has been published.
Buggiani et al. [24] compared subjects treated
with UVB microphototherapy and with
clobetasol propionate ointment. Excellent
repigmentation ([75%) was achieved by 61.1%
of patients in the UVB microphototherapy
group and by 56.2% of patients in the
clobetasol propionate ointment group. In the
CPF-treated group, the median repigmentation
scores on neck, upper limbs, lower limbs, and
trunk were significantly higher than in the NB-
UVB group in the same body sites. For the hand/
Table 1 Characteristics of the study population
Patients treated
with NB-UVB N (%)
Patients treated
with CPF N (%)
P value
Mean age ± SD (years) 47.2 ± 14.6 39.8 ± 13.6 0.049a
Male/female 16/14 12/18 0.301c
Pattern of vitiligo
Only nonsegmental 30 (100) 30 (100)
Acrofacial 1 (3.3) 1 (3.3) 1.000d
Generalized 17 (56.7) 16 (53.3)
Localized 12 (40.0) 13 (43.3)
Median duration of disease, years(interquartile range) 4.0 (3–23) 8.5 (4–20) 0.028b
Fitzpatrick’s skin phototype
Phototype I 0 (0) 0 (0)
Phototype II 4 (13.3) 11 (36.7)
Phototype III 14 (46.7) 13 (43.3) 0.125d
Phototype IV 8 (26.7) 3 (10)
Phototype V 4 (13.3) 3 (10)
Family history of vitiligo
Yes 8 (26.7) 5 (16.7) 0.532c
No 22 (73.3) 25 (83.3)
Comorbidities
None 24 (80) 19 (63.3)
Thyroid disease 1 (3.3) 9 (30) 0.020d
Others 5 (16.7) 2 (6.7)
NB-UVB narrow band-ultraviolet B phototherapy, CPF 0.05% clobetasol propionate foam
a T test
b Mann–Whitney test
c Chi-square test
d Fisher’s test
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wrists and feet/ankles, despite that both groups
showed low repigmentation levels, the median
scores were significantly higher in patients
treated with CPF. The location of lesions is the
most important factor in predicting the
response of vitiligo to therapy and previous
studies had already shown that face and neck
achieve better repigmentation than trunk and
extremities [16, 25, 26]. Another factor that may
contribute to a good response is the shorter
duration of disease [25]. Interestingly, in this
study the topical steroid therapy showed a
better clinical response, although the duration
of disease in the CPF group was significantly
longer as compared to the NB-UVB group. This
finding seems to confirm the good efficacy of
the new topical formulation of this superpotent
corticosteroid in patients with vitiligo.
The chronic use of topical corticosteroids
might cause side effect as skin atrophy, striae,
hypertrichosis, acneiform eruption, and
telangiectasia which are limiting factors in
vitiligo treatment [27]. CPF has been proposed
for long-term therapy in chronic dermatosis
[19–23]. Lacarrubba et al. [28] evaluated
through ultrasound imaging the atrophogenic
Table 2 Clinical efficacy of NB-UVB and CPF treatments for each body site
Patients treated
with NB-UVB N (%)
Patients treated
with CPF N (%)
P value
Neck
Number of treated patients (%) 10 (33.3) 8 (26.7) 0.573b
Repigmentation score, median (interquartile range) 2 (1–3) 4 (2–4) 0.005a
Upper limbs
Number of treated patients (%) 17 (56.7) 16 (53.3) 0.795b
Repigmentation score, median (interquartile range) 1 (1–3) 3 (1–4) 0.002a
Hand/wrists
Number of treated patients (%) 15 (50) 19 (63.3) 0.297b
Repigmentation score, median (interquartile range) 0 (0–2) 1 (1–2) \0.0001a
Trunk
Number of treated patients (%) 12 (40) 12 (40) 1.000b
Repigmentation score, median (interquartile range) 2 (1–2) 3 (1–4) 0.008a
Lower limbs
Number of treated patients (%) 15 (50) 11 (36.7) 0.297b
Repigmentation score, median (interquartile range) 1 (1–2) 3 (2–3) \0.0001a
Feet/ankles
Number of treated patients (%) 12 (40) 11 (36.7) 0.791b
Repigmentation score, median (interquartile score) 0 (0) 0 (0–1) 0.010a
NB-UVB narrowband-ultraviolet B phototherapy, CPF 0.05% clobetasol propionate foam
a Mann–Whitney test
b Chi-square test
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potential of once-daily application of CPF on
healthy skin and they did not observe any
ultrasound variations in skin thickness. Recent
studies treated vitiligo patients with 0.05%
clobetasol propionate ointment, twice a day
for 12 weeks with mild to moderate side effects
[24]. In the present study, the patients applied
CPF twice a day for 5 days/week for 12 weeks.
This therapeutic protocol has already been
proposed in alopecia areata by Tosti et al. [22]
who demonstrated the safety of this scheme.
Overall in this study the adverse effects were
rare. No adverse effect was reported in the NB-
UVB group. In the CPF-treated group, three
patients reported a slight and transient
erythema with itching which disappeared after
the next application and only in one woman
the treatment had to be stopped due to the
appearance of diffuse edema. Anyway the
difference in occurrence of side effects
observed in the two groups of treatment was
not significant. Therefore, these findings
suggest that in adult patients with vitiligo,
CPF and NB-UVB phototherapy are effective
treatment options with a good safety profile.
CPF has some additional benefits compared
with NB-UVB phototherapy; the treatment can
be self-managed by the patient and the results
of a good/excellent repigmentation require less
time to manifest (up to 3 months with CPF
versus up to 6 months with NB-UVB). All these
factors should be kept in mind when
considering the patient’s adherence to
treatment which is likely the most important
determinant of the therapeutic success.
This study is the first, to the best of the
authors’ knowledge, that evaluates the clinical
efficacy of the new foam vehicle of 0.05%
clobetasol propionate in the treatment of
vitiligo. Its efficacy and safety, the ease of
application, and relatively low cost of the
therapy prompted us to introduce this CPF
formulation in the treatment of vitiligo.
Fig. 1 Median repigmentation scores for anatomic sites,
by treatment regimen. Treatment outcome scores were ‘0,
absent’ (0%), ‘1, poor’ (1–25%), ‘2, moderate’ (26–50%),
‘3, good’ (51–75%), and ‘4, excellent’ ([75%)
Fig. 2 Vitiligo of the forearms before (a) and after (b) treatment with 0.05% clobetasol propionate foam
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CONCLUSION
The findings suggest a good efficacy of the CPF in
vitiligo in all the treated anatomic sites compared
to the NB-UVB phototherapy and a good safety
profile in a medium-term use. This new foam
formulation may expand the options currently
available for vitiligo therapy; however, further
investigations are needed to confirm the
preliminary observations. Since clobetasol
propionate is a well-known treatment for
vitiligo, and the results seems to demonstrate
the efficacy of the novel formulation of this drug,
in the future, it would be reasonable to compare
traditional clobetasol propionate formulations
against CPF to deepen the advantages brought by
the foam vehicle. It would also be interesting to
know the potential advantage introduced by the
new formulation of the foam (VersaFoam-EF
emollient foam technology which does not
contain any ethanol). Furthermore, combined
treatments seem to be presently superior to
monotherapies in terms of efficacy and safety.
It is an established fact that combination of NB-
UVB with topical treatment(s) is superior over
monotherapy [29]; therefore, further studies
would be opportune to evaluate not only the
relative efficiency of and patient’s compliance to
CPF against traditional clobetasol propionate
formulations alone, but also when combined
with NB-UVB.
BULLET POINTS
• Recently a new topic formulation of 0.05%
clobetasol propionate in thermophobic foam
(CPF) has been reported as an effective
treatment in several dermatoses, but no
data are reported in vitiligo.
• Based on the results of a retrospective study
on 60 vitiligo patients, we discuss the
efficacy and tolerability of CPF compared to
NB-UVB phototherapy.
• CPF is effective and seems to be superior to
NB-UVB phototherapy, with a good safety
profile.
• This is the first study that investigates the
clinical efficacy of CPF in the treatment of
vitiligo.
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